Effect of High Intensity Focused Electromagnetic Field on Postnatal Diastasis Recti

by palligoelme@gmail.com | Mar 2, 2026 | Clinical Trials

​ Conditions: Diastasis Recti Interventions: Other: A program of abdominal exercises; Device: High-intensity focused electromagnetic field Sponsors: Cairo University Not yet recruiting Conditions: Diastasis Recti Interventions: Other: A program of abdominal exercises;...

CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)

by palligoelme@gmail.com | Mar 2, 2026 | Clinical Trials

​ Conditions: Large-cell Lymphoma Interventions: Biological: Rapcabtagene autoleucel (YTB323) Sponsors: Stanford University; Novartis Not yet recruiting Conditions: Large-cell Lymphoma Interventions: Biological: Rapcabtagene autoleucel (YTB323) Sponsors: Stanford...

Auricular Stimulation for Functional Dyspepsia With Insomnia: Efficacy and Mechanisms

by palligoelme@gmail.com | Mar 2, 2026 | Clinical Trials

​ Conditions: Functional Dyspepsia; Insomnia; Brain and Nervous System Interventions: Behavioral: Auricular acupressure in concha area; Behavioral: Auricular acupressure in earlobe Sponsors: The First Affiliated Hospital of Zhejiang Chinese Medical University...

The Effect on Adolescents’ Cyberbullying/Cyber Victimization and Coping Skills of the Human Values-Oriented Cyberbullying Prevention Program

by palligoelme@gmail.com | Mar 2, 2026 | Clinical Trials

​ Conditions: Human Values-Oriented Cyberbullying Prevention Program Interventions: Behavioral: Human Values-Oriented Cyberbullying Prevention Program Sponsors: Pelin Büyüksandıç Özşen Recruiting Conditions: Human Values-Oriented Cyberbullying Prevention Program...

Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma

by palligoelme@gmail.com | Mar 2, 2026 | Clinical Trials

​ Conditions: Phase II; Sacituzumab; Tirumotecan; SMARCB1-deficient Renal Medullary Carcinoma Interventions: Drug: Sacituzumab tirumotecan Sponsors: M.D. Anderson Cancer Center; Merck Sharp & Dohme LLC Not yet recruiting Conditions: Phase II; Sacituzumab;...